Shenzhen University General Hospital
YuLi
Prospectively evaluate the safety and effectiveness of CD19/CD22 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.
Dual-target CAR-T Cells
B ALL
Relapse
Refractory B Acute Lymphoblastic Leukemia
Dual target CAR-T cell therapy
Phase 1
Phase 2
Prospectively evaluate the safety and effectiveness of CD19/CD22 dual-target CAR-T cells in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia. Strictly follow the inclusion criteria to screen eligible subjects for inclusion in clinical trials. The selected patients received CD19/CD22 dual-target CAR-T cell therapy. After the treatment is over, follow-up regularly to determine the survival status and follow-up treatment.
Study Type : | Interventional |
Estimated Enrollment : | 20 participants |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Clinical Trial of CD19/CD22 Dual Target CAR-T Cells in the Treatment of Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia |
Actual Study Start Date : | October 20, 2020 |
Estimated Primary Completion Date : | December 31, 2022 |
Estimated Study Completion Date : | December 31, 2022 |
Arm | Intervention/treatment |
---|---|
Experimental: Treatment group Dual target CAR-T cell therapy |
Biological: Dual target CAR-T cell therapy |
Ages Eligible for Study: | 14 Years to 75 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Shenzhen University General hospital
Shenzhen, Guangdong, China, 518055